期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 102, 期 9, 页码 2898-2908出版社
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.23504
关键词
pharmacokinetics/pharmacodynamics; computational biology; physiological model; pharmacokinetics; pharmacodynamics; allometry; nonlinear pharmacokinetics; antibody; PK/PD
Over the last two decades, there has been a simultaneous explosion in the levels of activity and capability in both monoclonal antibody (mAb) drug development and in the use of quantitative pharmacologic models to facilitate drug development. Both of these topics are currently areas of great interest to academia, the pharmaceutical and biotechnology industries, and to regulatory authorities. In this article, we summarize convergence of these two areas and discuss some of the current and historical applications of the use of mathematical-model-based techniques to facilitate the discovery and development of mAb therapeutics. We also consider some of the current issues and limitations in model-based antibody discovery/development and highlight areas of further opportunity. (C) 2013 Wiley Periodicals, Inc. and the American Pharmacists Association
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据